WO1993005818A1 - Diagnostic agents - Google Patents
Diagnostic agents Download PDFInfo
- Publication number
- WO1993005818A1 WO1993005818A1 PCT/EP1992/002254 EP9202254W WO9305818A1 WO 1993005818 A1 WO1993005818 A1 WO 1993005818A1 EP 9202254 W EP9202254 W EP 9202254W WO 9305818 A1 WO9305818 A1 WO 9305818A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnetometric
- ferromagnetic
- physiologically tolerable
- ferrimagnetic
- imaging
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Definitions
- This invention relates to the use of magnetic substances, in particular ferromagnetic and ferrimagnetic substances, as enhancing agents for diagnostic magnetometery, and in particular as contrast agents in magnetometric imaging, especially using a superconducting quantum interference device magnetometer (a SQUID) , preferably in combination with a magnetic resonance imager.
- a SQUID superconducting quantum interference device magnetometer
- SQUID magnetometers generally comprise a superconducting pick up coil system and a detector system (the SQUID) which itself comprises one or two Josephson junctions inserted into a loop of superconducting wire.
- the magnetic flux within such loops is quantized and changes in the magnetic field experienced by the pick up coils cause an immediate and measurable change in the current flowing through the detector.
- the SQUID magnetometers available include both single and multichannel devices, the latter being capable of detecting magnetic fields at plurality of locations simultaneously.
- SQUID magnetometers are capable of measuring magnetic fields as low as 10 "14 Tesla, one ten billionth the earth's magnetic field, and thus are able to detect magnetic fields generated by biological activity such as for example the fields of the order of 10' I3 T which are induced by the electrical activity of the brain.
- the sources of nerve signals can thus be traced to within a few millimeters.
- the SQUID may be designed to detect the magnetic field or, may be of the gradiometer type and which several designs exist.
- the sensitivity of SQUIDS has been such that the researchers' concentration has primarily been on three areas - the detection of electrical activity within body tissues by detection of the accompanying magnetic field changes, the in vivo determination of iron concentrations in the liver in order to detect iron overload or iron deficiency there, and the detection of ferromagnetic particle contamination in the lungs.
- the magnetic fields detected by the SQUIDS arise from normal or stimulated nerve activity or from the normal presence of (paramagnetic) iron in the liver.
- particle contamination is by magnetic particles, e.g. of magnetite, and their magnetic effect is first maximized by placing the subject in a magnetic field. The resultant magnetization is detectable by a SQUID for the period of months over which it decays.
- the present invention provides the use of a physiologically tolerable, particulate, free or matrix-borne, ferrimagnetic or ferromagnetic material for the manufacture of a diagnostic agent for administration into the gastrointestinal tract, the reproductive tract, the urinary tract, closed body cavities (e.g. into the synovial fluid or the vasculature) , or the musculature for magnetometric imaging of the human or non-human, preferably mammalian, animal body.
- the invention also provides a method of generating a magnetometric image of the human or non-human animal body which method comprises administering into the gastrointestinal tract, the reproductive tract, the urinary tract, closed body cavities (e.g. into the synovial fluid or the vasculature) or the musculature of said body a physiologically tolerable particulate ferromagnetic or ferrimagnetic material and • generating a magnetometric image of at least a part of said body into which said material distributes, in particular generating a two or three dimensional structural image and preferably but not essentially using a SQUID based imaging device, especially a multichannel SQUID imager.
- a method of generating a magnetometric image of the human or non-human animal body comprises administering into the gastrointestinal tract, the reproductive tract, the urinary tract, closed body cavities (e.g. into the synovial fluid or the vasculature) or the musculature of said body a physiologically tolerable particulate ferromagnetic
- the invention also provides a process for detecting variations in magnetic susceptibility within a human or non-human animal body which process comprises administering into the gastrointestinal tract, the reproductive tract, the urinary tract, closed body cavities (e.g.
- the invention also provides the use of a physiologically tolerable particulate ferromagnetic or ferrimagnetic material, and i particular free or matrix-borne, ferromagnetic or ferrimagnetic particles, for the manufacture of a diagnostic composition for use in the process according to the invention.
- the method and process of the invention may be performed using any magnetometric technique but are particularly suited to the use of multichannel SQUID based magnetometers.
- the ferrimagnetic or ferromagnetic substances used according to the invention and for convenience referred to herein as magnetometric diagnostic agents may, in view of the sensitivity of SQUID magnetometers, be any such material which is biotolerable in the dosages and with the administration form and route that is used.
- the diagnostic agent There is of course no necessity to pre-magnetize the subject following administration of the diagnostic agent before transferring the subject to the magnetometer location (generally a region of homogeneous magnetic field or a magnetically shielded room) .
- the contrast agent may be pre-magnetised before administration and it may also be advantageous to pre- treat the magnetic substance to prevent conglomeration thus obtaining a maximum field for a given concentration of subtance.
- the process and method of the invention can be performed with or without the imposition of an external magnetic field (besides or in place of the earth's natural magnetic field that is) .
- Imposed fields can be variant, e.g. pulsed, or invariant.
- This field can be relatively localized in effect and can be as low as lO ⁇ T but in one convenient embodiment may be the primary field, generally of up to 10' ⁇ , generated by the primary coils of a magnetic resonance imager.
- the literature contains many suggestions for the formulation of paramagnetic particles and in particular suggests that the particles can be administered either free (i.e. uncoated and not bound to any other substance) or coated (e.g. dextran or lipid coated) , or carried by or embedded in a matrix particle (e.g. a polysaccharide) or bound to an organ or tissue targetting molecule, e.g. a natural or synthetic biomolecule or derivative thereof such as an antibody, an antibody fragment, a protein or protein fragment, a hormone, a lectin, lymphokine, a growth factor, ferritin or a nerve adhesion molecule (see for example O- A-92/04916) .
- a matrix particle e.g. a polysaccharide
- an organ or tissue targetting molecule e.g. a natural or synthetic biomolecule or derivative thereof such as an antibody, an antibody fragment, a protein or protein fragment, a hormone, a lectin, lymphokine, a growth factor, ferritin or a
- the coating is a biologically relatively inert material such as a polysaccharide (e.g. dextran) , a naturally occurring protein or a lipid it is preferred that the coating give the particle an overall charge, preferably a negative charge.
- a biologically relatively inert material such as a polysaccharide (e.g. dextran)
- a naturally occurring protein or a lipid it is preferred that the coating give the particle an overall charge, preferably a negative charge.
- MD agents are also of particular interest in the imaging of the liver, spleen and lymphatic due to the action of the reticuloendothelial system (RES) in removing such particles from the blood stream.
- RES reticuloendothelial system
- the MD agents can, as mentioned above also be administered into other closed body cavities, such as the joints, e.g. the knee.
- MD agents and especially particulate agents may also be used to advantage in the magnetometric diagnosis or imaging of body ducts and cavities having external voidance ducts, e.g. the gastrointestinal tract, the bladder and the uterus, where the MD agent can be administered orally, rectally or through a catheter into the body cavity of interest.
- axonal imaging, lymphatic system imaging or synovial fluid imaging by magnetometry one may use superparamagnetic and paramagnetic materials coated or labelled as discussed above and the use of paramagnetic, superparamagnetic, ferromagnetic and ferrimagnetic materials for the manufacture of contrast agents for magnetometric axonal imaging or magnetometric lymph node imaging form a further aspect of the invention.
- superparamagnetic and paramagnetic materials are discussed in WO-A-91/15243.
- Hepatocytes also have specific lectins and sugar moieties present on their surface. The latter causes specific oligosaccharides, glycoproteins and lectins to accumulate in the hepatocyte compartment of the liver.
- the Kupffer cells as well as the endothelial cells of the liver also possess unique receptors (e.g. lectins) on their surface, causing other types of ligands (e.g. glycoproteins) to accumulate in these compartments.
- the endothelial cells of the liver have receptors for specific molecules such as hyaluronic acid, enabling other types of targeting vehicles also to be used for this compartment.
- targeting vehicles will cause accumulation in normal organs, and if these are deformed and non-homogeneous due to disease, MD agents attached to such vehicles will provide important diagnostic information.
- targeting vehicles with affinity for disease-specific structures should be employed.
- pathologically altered cells e.g. tumour cells
- monoclonal antibodies reacting with a number of such structures have been developed.
- Pathology-specific monoclonal antibodies coupled to MD agents can thus be used to obtain disease information, e.g. by visualization.
- Thrombi contain a number of specific structures, for instance fibrin. Consequently, MD agents coupled to fibrin-specific antibodies will after intravenous injection accumulate in the clots, and can be used for localization of the thrombi.
- tPA and hyrudin have affinity for fibrin.
- tPA or hyrudin coupled MD agents would thus accumulate in thrombi and be useful for their detection.
- magnetic particle containing contrast media are administered parenterally, and especially intravascularly, the biodegradation and ultimate excretion of the particle metabolites may be enhanced by formulating the particles together with a chelating agent as described in WO-A-89/11873.
- the ferri- or ferromagnetic particles themselves may be of any material which, although preferably non- radioactive (unless the particles are also intended to be detected by their radioactive decay emissions) , exhibits ferri- or ferromagnetism in domain and sub- domain sized crystals.
- the particles will be of a magnetic metal or alloy, e.g. of pure iron, but more preferably they will be of a magnetic iron oxide, e.g. magnetite, or a ferrite such as cobalt, nickel or manganese ferrites.
- the magnetic particles useful according to the invention will preferably have average overall particle sizes up to 10 ⁇ m, especially up to 1 ⁇ m. Generally however the particle sizes for individual magnetic crystals will preferably up to l ⁇ m, especially up to 400 nm. For administration into the systemic vasculature or the musculature the overall particle size will particularly preferably be up to 800 nm, especially up to 500 nm. For administration into the GI tract or the reproductive or urinary tracts overall particle size will preferably be up to millimeter size, e.g. 100 nm - 5 ⁇ m, especially 200 nm - 3 ⁇ m. The magnetic crystals of course will be at least single domain size. Generally this is of the order of 100 nm.
- the dosages of the MD agent used according to the method of the present invention will vary according to the precise nature of the MD agent used, of the magnetometer being used and of the tissue or organ of interest. Preferably however the dosage should be kept as low as possible while still achieving a detectable variation in magnetic susceptibility.
- the MD agents used according to the invention should be administered in a quantity sufficient to produce a concentration, expressed in terms of susceptibility of at least 10 "9 emu/g, preferably at least 5 x 10" 9 emu/g, especially at least 10" 8 emu/g.
- the invention provides a magnetic susceptibility MD medium in aqueous form containing a physiologically tolerable ferrimagnetic or ferromagnetic substance together with at least one pharmaceutical carrier or excipient, the magnetic susceptibility of said medium (at STP) being in the range 10' 12 to lO" 6 , preferably 10' u to 2 x 10" 7 , especially preferably 10" 10 to 5 x 10" 8 , in particular 10" 9 to 10 "8 , emu/g.
- the novel MD media will conveniently contain the magnetic metal at a concentration of at least 10" 1 M, generally at least 1O "I0 M, preferably at least 10 " ⁇ , in particular at least 0.05 mM, especially at least 0.2 mM, more preferably at least 0.3 mM, most preferably at least 1.0 mM, e.g. 0.0002 to 2 M, more especially 0.0003 to 1.5 M.
- the MD media of the invention may contain particularly low concentrations of the contrast agent where it is a highly specifically targeted material.
- minimum dosages of the order of 10' 14 M/Kg may be adequate
- liver specific agents minimum dosages may be of the order of 10 "U M/Kg and for agents which distribute broadly within the body minimum dosages of 10" I0 M/kg may be appropriate.
- These will generally be administered in volumes of 0.1 ml to 1000 ml.
- the upper limit for MD agent dosages will be generally comparable to that for MRI contrast agents and may be dictated by toxicity constraints.
- the appropriate dosage will generally lie in the range 0.02 ⁇ mol to 3 mmol paramagnetic metal/kg bodyweight, especially 1 ⁇ mol to 1.5 mmol/kg, particularly 0.01 to 0.5, and more especially 0.1 to 0.4 mmol/kg.
- the MD agent concentrations required will of course be higher than are needed using SQUID magnetometers.
- MD agents may be formulated with conventional pharmaceutical or veterinary aids, for example, stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc., and may be in a form suitable for enteral or parenteral administration, e.g. oral, rectal, intravascular etc. Particularly preferably the MD agents will be in forms suitable for ingestion, injection or infusion directly or after dispersion in or dilution with a physiologically acceptable carrier medium, e.g. water for injections.
- a physiologically acceptable carrier medium e.g. water for injections.
- the contrast agents may be formulated in conventional administration forms such as powders, solutions, suspensions, dispersions etc., however solutions, suspensions and dispersions in physiologically acceptable carrier media will generally be preferred.
- the MD agents may therefore be formulated for administration using physiologically acceptable carriers or excipients in a manner fully within the skill of the art.
- the MD agents optionally with the addition of pharmaceutically acceptable excipients, may be suspended or dissolved in an aqueous medium, with the resulting solution or suspension then being sterilized.
- suitable additives include, for example, physiologically biocompatible buffers chelating agents (as for example DTPA or DTPA-bisamide (e.g.
- calcium chelate complexes as for example salt forms of the calcium DTPA complex or the calcium DTPA- bisamide complex, such as NaCaDTPA-bisamide
- additions e.g. 1 to 50 mole percent
- calcium or sodium salts for example, calcium chlorie, calcium ascorbate, calcium gluconate or calcium lactate and the like
- Parenterally administerable forms e.g., intravenous solutions
- Suitable vehicles include aqueous vehicles customarily used for administering parenteral solutions such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection and other solutions such as are described in Remington's Pharmaceutical Sciences, 15th ed. , Easton: Mack Publishing Co., pp.
- the solutions can contain preservatives, antimicrobial agents, buffers and antioxidants conventionally used for parenteral solutions, excipients and other additives which are compatible with the MD agents and which will not interfere with the manufacture, storage or use of the products.
- the MRI contrast media can be used as MD media it will be particularly convenient to investigate the subject using MRI to supplement or confirm diagnostic information derived from the magnetometer investigations.
- images from MRI or other conventional imaging modalities may be used to provide a "native" image onto which the magnetometric information or image may be superimposed - this is of particular value where the biodistribution of the magnetometric contrast agent is very specific.
- the magnetometric investigation technique of the invention may be used to investigate the distribution of materials administered as MRI contrast agents, particularly preferably using relatively inexpensive non-SQUID magnetometers.
- the invention provides a magnetic resonance imaging apparatus, characterized in that it is provided with magnetometric detection means.
- the invention provides a magnetometer adapted for the detection of magnetic resonance imaging contrast agents within a human or non human animal subject and preferably also for the generation of a magnetometric image of said subject, i.e. being a combination of a magnetometer and MRI imager.
- a magnetometer/MRI imager may be produced by straightforward modification of existing MRI apparatus to incorporate suitable magnetometric detector means.
- a Hall probe on an array of such probes may be so mounted in an MRI imager as to allow a body within such an imager to be scanned eg.
- a static array of Hall probes may be disposed about the imaging cavity of the MRI imager so allowing a magnetometric image to be generated without requiring physical displacement of the Hall probes.
- the operation of the Hall probes and the magnetometric image generation may conveniently be controlled by the same computer as controls its MRI imaging operations.
- the substances are dry blended and granulated with a granulating liquid of the following composition:
- Iron fine powder (Riedel-deHaen no. 12310) 5 g Purified water 1800 g
- the granulated is dried and screened to give a granulate fraction of 0.3 to 1.5 mm.
- 10 g of the granulate suspended in 100 ml water will give a viscosity of approximately 2500 cps when fully hydrated.
- the viscosity remains sufficiently low (less than about 200 cps) for easy administration, e.g. by ingestion.
- the hydroxyethyl cellulose was dispersed in water with stirring for 2 hours. Saccharin sodium, mannitol and a solution of the essences, and methyl and propyl parahydroxybenzoate in ethanol were slowly added. The magnetic particles were dispersed in the solution under vigorous stirring. The suspension contained 0.05 mg Fe/g.
- Multi-channel SQUID analysis of 0.5% agar gels containing MD agents Multi-channel SQUID analysis of 0.5% agar gels containing MD agents.
- MD agent Black iron oxide particles from Anstead Ltd. , England
- MD agent Black iron oxide particles from Anstead Ltd., England
- Multi-channel SQUID analysis of the same samples as described in Example 3-4 after magnetization of the samples with a small, strong (about 0.3T) permanent magnet showed enhanced magnetometric effect compared to the non-magetized samples.
- the MD media of Examples 1 and 2 are diluted, 1 part by volume with 99 parts by volume of water for injections to produce more dilute contrast media suitable for use with sensitive SQUID based magnetometers.
- Still lower concentrations e.g. at the 10' 10 -10" 6 M level, can be produced by further dilution.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU26551/92A AU662927B2 (en) | 1991-09-26 | 1992-09-26 | Diagnostic agents |
EP92920342A EP0605563A1 (en) | 1991-09-26 | 1992-09-26 | Diagnostic agents |
JP5505814A JPH06510777A (en) | 1991-09-26 | 1992-09-26 | diagnostic agent |
RU94019333A RU2137501C1 (en) | 1991-09-26 | 1992-09-26 | Utilization of physiologically acceptable corpuscular ferromagnetic or ferromagnetic material, method of magnetometric imaging, change-revealing process, utilization of physiologically acceptable paramagnetic, superparamagnetic, ferromagnetic or ferromagnetic particles, and imaging device |
US08/199,252 US5496534A (en) | 1991-09-26 | 1992-09-28 | Squid magnetometry using ferri-and ferromagnetic particles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9120508.8 | 1991-09-26 | ||
GB919120508A GB9120508D0 (en) | 1991-09-26 | 1991-09-26 | Diagnostic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993005818A1 true WO1993005818A1 (en) | 1993-04-01 |
Family
ID=10702022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1992/002254 WO1993005818A1 (en) | 1991-09-26 | 1992-09-26 | Diagnostic agents |
Country Status (8)
Country | Link |
---|---|
US (2) | US5496534A (en) |
EP (1) | EP0605563A1 (en) |
JP (1) | JPH06510777A (en) |
AU (1) | AU662927B2 (en) |
CA (1) | CA2116675A1 (en) |
GB (1) | GB9120508D0 (en) |
RU (1) | RU2137501C1 (en) |
WO (1) | WO1993005818A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19503664A1 (en) * | 1995-01-27 | 1996-08-01 | Schering Ag | Methods and compounds for magnetorelaxometric detection of analytes and their use |
US6713173B2 (en) | 1996-11-16 | 2004-03-30 | Nanomagnetics Limited | Magnetizable device |
US6815063B1 (en) | 1996-11-16 | 2004-11-09 | Nanomagnetics, Ltd. | Magnetic fluid |
US6896957B1 (en) | 1996-11-16 | 2005-05-24 | Nanomagnetics, Ltd. | Magnetizable device |
US6986942B1 (en) | 1996-11-16 | 2006-01-17 | Nanomagnetics Limited | Microwave absorbing structure |
WO2006030043A1 (en) * | 2004-08-06 | 2006-03-23 | Daniel Serrano Gil | System for detecting the presence of hyperactive cell accumulations in an animal organism and associated detection method |
WO2007088051A2 (en) | 2006-01-31 | 2007-08-09 | Bayer Schering Pharma Aktiengesellschaft | Modulation of mdl-1 activity for treatment of inflammatory disease |
US7737252B2 (en) | 2000-09-26 | 2010-06-15 | Ge Healthcare As | Peptide-based compounds |
WO2014144708A1 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
EP3412303A1 (en) | 2017-06-08 | 2018-12-12 | Medizinische Universität Innsbruck | Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy |
RU2685811C1 (en) * | 2018-06-04 | 2019-04-23 | Климентий Николаевич Югай | Method for detection and elimination of separate cancer cells and their clusters |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9120508D0 (en) * | 1991-09-26 | 1991-11-06 | Nycomed As | Diagnostic agents |
US5674468A (en) * | 1992-03-06 | 1997-10-07 | Nycomed Imaging As | Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons |
US5842986A (en) * | 1995-08-16 | 1998-12-01 | Proton Sciences Corp. | Ferromagnetic foreign body screening method and apparatus |
US7047059B2 (en) * | 1998-08-18 | 2006-05-16 | Quantum Magnetics, Inc | Simplified water-bag technique for magnetic susceptibility measurements on the human body and other specimens |
US6496713B2 (en) | 1996-06-25 | 2002-12-17 | Mednovus, Inc. | Ferromagnetic foreign body detection with background canceling |
US20020115925A1 (en) * | 1996-06-25 | 2002-08-22 | Avrin William F. | Ferromagnetic foreign body detection utilizing eye movement |
US6965792B2 (en) * | 1996-06-25 | 2005-11-15 | Mednovus, Inc. | Susceptometers for foreign body detection |
WO1998037826A1 (en) * | 1997-02-26 | 1998-09-03 | Aesculap Meditec Gmbh | Marker for determining its position in a cavity inside the organism of a living being |
US6470220B1 (en) * | 1999-03-29 | 2002-10-22 | The Regents Of The University Of California | Diagnosis and treatment of cancers using in vivo magnetic domains |
JP4171139B2 (en) * | 1999-07-21 | 2008-10-22 | 住友電気工業株式会社 | Immunoassay method and apparatus using magnetic substance labeling |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7541184B2 (en) * | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US20030235908A1 (en) * | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US20030119185A1 (en) * | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
EP1526171A1 (en) * | 2000-02-24 | 2005-04-27 | Xcyte Therapies, Inc | Simultaneous stimulation and concentration of cells |
KR20030032922A (en) * | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) * | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US20020019048A1 (en) * | 2000-05-25 | 2002-02-14 | Ronald Berenson | Methods for restoring or enhancing T-cell immune surveillance following naturally or artificially induced immunosuppression |
DE10151778A1 (en) * | 2001-10-19 | 2003-05-08 | Philips Corp Intellectual Pty | Method for determining the spatial distribution of magnetic particles |
US6693426B1 (en) * | 2002-02-09 | 2004-02-17 | Intematix Corporation | Spatially resolved spin resonance detection |
US20030216632A1 (en) * | 2001-10-29 | 2003-11-20 | Mednovus, Inc. | Ferromagnetic sensing method and apparatus |
US20030083588A1 (en) * | 2001-10-29 | 2003-05-01 | Mcclure Richard J. | Pre-screening utilizing magnetic resonance imaging field |
ES2422193T3 (en) * | 2002-06-28 | 2013-09-09 | Life Technologies Corp | Methods to restore the immune repertoire in patients with immunological defects related to autoimmunity and transplantation of hematopoietic organs or stem cells |
US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
US20040224402A1 (en) * | 2003-05-08 | 2004-11-11 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific T cells |
CA2539716A1 (en) * | 2003-09-22 | 2005-04-07 | Xcyte Therapies, Inc. | Compositions and methods to accelerate hematologic recovery |
US8060179B1 (en) | 2006-11-16 | 2011-11-15 | Scientific Nanomedicine, Inc. | Biomagnetic detection and treatment of Alzheimer's Disease |
US8118754B1 (en) | 2007-11-15 | 2012-02-21 | Flynn Edward R | Magnetic needle biopsy |
US7309316B1 (en) | 2004-03-01 | 2007-12-18 | Flynn Edward R | Magnetic needle biopsy |
US20050283226A1 (en) * | 2004-06-18 | 2005-12-22 | Scimed Life Systems, Inc. | Medical devices |
US9964469B2 (en) | 2005-02-28 | 2018-05-08 | Imagion Biosystems, Inc. | Magnetic needle separation and optical monitoring |
JP4706075B2 (en) * | 2005-04-11 | 2011-06-22 | 学校法人金沢工業大学 | Magnetic measuring apparatus and magnetic measuring method |
US8212554B2 (en) * | 2005-05-11 | 2012-07-03 | The University Of Houston System | Intraluminal magneto sensor system and method of use |
WO2006122278A2 (en) * | 2005-05-11 | 2006-11-16 | The University Of Houston System | A magneto sensor system and method of use |
US8447379B2 (en) | 2006-11-16 | 2013-05-21 | Senior Scientific, LLC | Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof |
JP2008212505A (en) * | 2007-03-07 | 2008-09-18 | Hitachi Ltd | Magnetic resonance imaging apparatus |
DE102007036570A1 (en) * | 2007-08-03 | 2009-02-19 | Siemens Ag | Screening test for detection of prostate disease and device and diagnostic substance for performing the test |
BRPI0917064A2 (en) * | 2008-12-08 | 2020-08-11 | Koninklijke Philips Electronics N.V. | configuration to detect and / or locate a magnetic material in an action region, method to detect and / or locate a magnetic material in an action region and computer program |
EP2375975A1 (en) * | 2008-12-12 | 2011-10-19 | Philips Intellectual Property & Standards GmbH | Arrangement and method for measuring the local velocity of a liquid |
WO2010125510A1 (en) * | 2009-04-30 | 2010-11-04 | Koninklijke Philips Electronics N.V. | Arrangement and method for influencing and/or detecting magnetic particles and for magnetic resonance imaging |
JP5805651B2 (en) | 2009-11-06 | 2015-11-04 | サイエンティフィック ナノメディスン, インコーポレイテッドScientific Nanomedicine, Inc. | Detection, measurement, and imaging of cells and other biological materials such as cancer using target nanoparticles and their magnetic particles |
US10194825B2 (en) | 2009-11-06 | 2019-02-05 | Imagion Biosystems Inc. | Methods and apparatuses for the localization and treatment of disease such as cancer |
US8593141B1 (en) | 2009-11-24 | 2013-11-26 | Hypres, Inc. | Magnetic resonance system and method employing a digital squid |
US8970217B1 (en) | 2010-04-14 | 2015-03-03 | Hypres, Inc. | System and method for noise reduction in magnetic resonance imaging |
US11136543B1 (en) | 2020-02-11 | 2021-10-05 | Edward R. Flynn | Magnetic cell incubation device |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989011873A1 (en) * | 1988-06-03 | 1989-12-14 | Nycomed As | Magnetic particle-containing compositions |
WO1990007322A1 (en) * | 1988-12-19 | 1990-07-12 | David Gordon | Diagnosis and treatment of viral effects |
WO1991015243A1 (en) * | 1990-04-02 | 1991-10-17 | Cockbain, Julian, Roderick, Michaelson | Diagnostic agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US4615879A (en) * | 1983-11-14 | 1986-10-07 | Vanderbilt University | Particulate NMR contrast agents for gastrointestinal application |
SE463651B (en) * | 1983-12-21 | 1991-01-07 | Nycomed As | DIAGNOSTIC AND CONTRACTOR |
GB8408127D0 (en) * | 1984-03-29 | 1984-05-10 | Nyegaard & Co As | Contrast agents |
GB8431305D0 (en) * | 1984-12-12 | 1985-01-23 | Ici Plc | Extraction of metals |
US4899755A (en) * | 1985-05-08 | 1990-02-13 | The General Hospital Corporation | Hepatobiliary NMR contrast agents |
US4827945A (en) * | 1986-07-03 | 1989-05-09 | Advanced Magnetics, Incorporated | Biologically degradable superparamagnetic materials for use in clinical applications |
US4996991A (en) * | 1986-07-18 | 1991-03-05 | Gordon Robert T | Method for following the distribution of particles in neurological or neuromuscular tissue and cells |
US4813399A (en) * | 1986-07-18 | 1989-03-21 | Gordon Robert T | Process for the treatment of neurological or neuromuscular diseases and development |
US5023072A (en) * | 1988-08-10 | 1991-06-11 | University Of New Mexico | Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract |
GB9120508D0 (en) * | 1991-09-26 | 1991-11-06 | Nycomed As | Diagnostic agents |
-
1991
- 1991-09-26 GB GB919120508A patent/GB9120508D0/en active Pending
-
1992
- 1992-09-26 JP JP5505814A patent/JPH06510777A/en not_active Ceased
- 1992-09-26 EP EP92920342A patent/EP0605563A1/en not_active Withdrawn
- 1992-09-26 CA CA002116675A patent/CA2116675A1/en not_active Abandoned
- 1992-09-26 WO PCT/EP1992/002254 patent/WO1993005818A1/en not_active Application Discontinuation
- 1992-09-26 AU AU26551/92A patent/AU662927B2/en not_active Ceased
- 1992-09-26 RU RU94019333A patent/RU2137501C1/en active
- 1992-09-28 US US08/199,252 patent/US5496534A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/483,168 patent/US5735279A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989011873A1 (en) * | 1988-06-03 | 1989-12-14 | Nycomed As | Magnetic particle-containing compositions |
WO1990007322A1 (en) * | 1988-12-19 | 1990-07-12 | David Gordon | Diagnosis and treatment of viral effects |
WO1991015243A1 (en) * | 1990-04-02 | 1991-10-17 | Cockbain, Julian, Roderick, Michaelson | Diagnostic agents |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19503664A1 (en) * | 1995-01-27 | 1996-08-01 | Schering Ag | Methods and compounds for magnetorelaxometric detection of analytes and their use |
DE19503664C2 (en) * | 1995-01-27 | 1998-04-02 | Schering Ag | Magnetorelaxometric detection of analytes |
US6713173B2 (en) | 1996-11-16 | 2004-03-30 | Nanomagnetics Limited | Magnetizable device |
US6815063B1 (en) | 1996-11-16 | 2004-11-09 | Nanomagnetics, Ltd. | Magnetic fluid |
US6896957B1 (en) | 1996-11-16 | 2005-05-24 | Nanomagnetics, Ltd. | Magnetizable device |
US6986942B1 (en) | 1996-11-16 | 2006-01-17 | Nanomagnetics Limited | Microwave absorbing structure |
US7737252B2 (en) | 2000-09-26 | 2010-06-15 | Ge Healthcare As | Peptide-based compounds |
US8258101B2 (en) | 2000-09-26 | 2012-09-04 | Ge Healthcare As | Peptide-based compounds |
ES2255830A1 (en) * | 2004-08-06 | 2006-07-01 | Daniel Serrano Gil | System for detecting the presence of hyperactive cell accumulations in an animal organism and associated detection method |
WO2006030043A1 (en) * | 2004-08-06 | 2006-03-23 | Daniel Serrano Gil | System for detecting the presence of hyperactive cell accumulations in an animal organism and associated detection method |
WO2007088051A2 (en) | 2006-01-31 | 2007-08-09 | Bayer Schering Pharma Aktiengesellschaft | Modulation of mdl-1 activity for treatment of inflammatory disease |
WO2014144708A1 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
EP3412303A1 (en) | 2017-06-08 | 2018-12-12 | Medizinische Universität Innsbruck | Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy |
WO2018224665A1 (en) | 2017-06-08 | 2018-12-13 | Medizinische Universität Innsbruck | Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy |
RU2685811C1 (en) * | 2018-06-04 | 2019-04-23 | Климентий Николаевич Югай | Method for detection and elimination of separate cancer cells and their clusters |
Also Published As
Publication number | Publication date |
---|---|
AU662927B2 (en) | 1995-09-21 |
JPH06510777A (en) | 1994-12-01 |
RU2137501C1 (en) | 1999-09-20 |
AU2655192A (en) | 1993-04-27 |
CA2116675A1 (en) | 1993-04-01 |
GB9120508D0 (en) | 1991-11-06 |
RU94019333A (en) | 1996-08-20 |
US5496534A (en) | 1996-03-05 |
EP0605563A1 (en) | 1994-07-13 |
US5735279A (en) | 1998-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5496534A (en) | Squid magnetometry using ferri-and ferromagnetic particles | |
EP0523116B1 (en) | Use of superparamagnetic particles for magnetometric analysis (SQUID) | |
EP0177545B2 (en) | Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents | |
US4770183A (en) | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents | |
US4827945A (en) | Biologically degradable superparamagnetic materials for use in clinical applications | |
Lawaczeck et al. | Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting: pre-clinical profile of SH U555A | |
US7396589B2 (en) | Core-shell magnetic nanoparticles comprising an inner-transition element | |
Josephson et al. | The effects of iron oxides on proton relaxivity | |
US4951675A (en) | Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging | |
Renshaw et al. | Immunospecific NMR contrast agents | |
US5128121A (en) | Mixture of a positive and negative contrast agent for magnetic resonance imaging | |
US5023072A (en) | Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract | |
US5219554A (en) | Hydrated biodegradable superparamagnetic metal oxides | |
US20050201941A1 (en) | Magnetic nanoparticle | |
Hemmingsson et al. | Relaxation enhancement of the dog liver and spleen by biodegradable superparamagnetic particles in proton magnetic resonance imaging | |
Josephson et al. | The magnetic properties of some materials affecting MR images | |
Corot et al. | Superparamagnetic contrast agents | |
Lönnemark et al. | Oral superparamagnetic particles for magnetic resonance imaging: effect in plain and viscous aqueous suspensions | |
Ferrucci | Iron oxide enhanced MR imaging of the liver and spleen: review of the first five years | |
Laurent et al. | Contrast agents for MRI: recent advances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU JP KR RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2116675 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992920342 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2119145 Country of ref document: CA Kind code of ref document: A Ref document number: 2119145 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08199252 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992920342 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992920342 Country of ref document: EP |